Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.
Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults
IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.
IDWeek 2024: Novavax Reports Positive Data for Novel Influenza and Flu-COVID-19 Combination Vaccines
IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.
IDWeek 2024: Merck’s Investigational 21-Valent Pneumococcal Vaccine Shows Positive Immune Responses in At-Risk Adults
V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.
Boost in CRC Screening after USPSTF Recommendation: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Next-Gen Noninvasive CRC Screening Test: Daily Dose
New Data for Arexvy Show Vaccine Efficacy Through 3 RSV Seasons in Older Adults
Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.